Free Trial
→ JD Vance Predicts: Wall Street vs. Trump & Your Money (From Priority Gold) (Ad) Free ACAD Stock Alerts

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

ACADIA Pharmaceuticals logo
$16.27 +0.06 (+0.37%)
(As of 11/20/2024 ET)
Compare

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 17 Analyst Ratings
Sell
0
Hold
6
Buy
11

Based on 17 Wall Street analysts who have issued ratings for ACADIA Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 6 have given a hold rating, and 11 have given a buy rating for ACAD.

Consensus Price Target

$25.56
57.11% Upside
According to the 17 analysts' twelve-month price targets for ACADIA Pharmaceuticals, the average price target is $25.56. The highest price target for ACAD is $42.00, while the lowest price target for ACAD is $19.00. The average price target represents a forecasted upside of 57.11% from the current price of $16.27.
Get the Latest News and Ratings for ACAD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors.

Sign Up

ACAD Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24		1 Month Ago
10/23/23 to 10/22/24		3 Months Ago
8/24/23 to 8/23/24		1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.56$25.56$25.56$35.67
Forecasted Upside57.11% Upside76.05% Upside60.37% Upside62.19% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ACAD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ACADIA Pharmaceuticals Stock vs. The Competition

TypeACADIA PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.65
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside57.11% Upside26,931.57% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent ACAD News
Neutral News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2024HC Wainwright
2 of 5 stars		 Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00+70.99%
11/7/2024Needham & Company LLC
2 of 5 stars		 Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00+77.33%
10/10/2024Raymond James
4 of 5 stars		D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingMarket Perform
8/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$30.00 ➝ $23.00+48.67%
8/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$25.00 ➝ $23.00+49.45%
8/7/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$37.00 ➝ $28.00+82.17%
8/7/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$29.00 ➝ $26.00+67.31%
8/7/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$28.00 ➝ $20.00+6.10%
6/27/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		E. Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOutperform$31.00+100.00%
5/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$26.00 ➝ $22.00+44.64%
5/9/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold ➝ Hold$26.00 ➝ $21.00+30.84%
5/9/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$31.00 ➝ $28.00+63.46%
5/9/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$25.00 ➝ $21.00+22.59%
5/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $19.00+11.44%
3/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$29.00 ➝ $25.00+40.53%
2/7/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform ➝ Market Outperform$42.00+66.67%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy ➝ Buy$25.00+18.54%
8/3/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$39.00 ➝ $38.00+36.01%
4/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$93.00 ➝ $95.00+363.41%
3/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$22.00 ➝ $25.00+28.80%
3/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$10.00 ➝ $15.00-22.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:57 AM ET.


ACAD Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $25.56, with a high forecast of $42.00 and a low forecast of $19.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares.

According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 57.11% based on their 12-month stock forecasts.

ACADIA Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, and Raymond James in the past 90 days.

Analysts like ACADIA Pharmaceuticals less than other "medical" companies. The consensus rating score for ACADIA Pharmaceuticals is 2.65 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ACAD compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NASDAQ:ACAD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time N...
Behind the Markets | Sponsored